Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 172-177

  Atar, Dan ^a   Malinin, Alex ^b   Takserman, Aviv ^a   Pokov, Alex ^b   Van Zyl, Louis ^c   Tanguay, Jean Francois ^d   Lesperance, Francois ^d   Serebruany, Victor ^b,e  

^a UNIVERSITY OF OSLO   (Norway)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Osier Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DINORCITALOPRAM; DRUG METABOLITE; ESCITALOPRAM; GLYCOPROTEIN IB; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 3; NORCITALOPRAM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIGENS, NEOPLASM; BLOOD PLATELETS; CITALOPRAM; FEMALE; FLOW CYTOMETRY; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; NEOPLASM PROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX;

EID: 33646680740     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000204047.76286.6e     Document Type: Article

References (52)

1. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802-813.
2. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction - impact on 6-month survival. JAMA. 1993;270:1819-1825.
3. Carney RM, Blumenthal JA, Freedland KE, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med. 2004;66:466-474.
4. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66:305-315.
5. Akhtar MS, Malik SB, Ahmed MM. Symptoms of depression and anxiety in post-myocardial infarction patients. Coll Physicians Surg Pak. 2004;14:615-618.
6. Grace SL, Abbey SE, Irvine J, et al. Prospective examination of anxiety persistence and its relationship to cardiac symptoms and recurrent cardiac events. Psychother Psychosom. 2004;73:344-352.
7. Lane D, Carroll D, Ring C, et al. The prevalence and persistence of depression and anxiety following myocardial infarction. Br J Health Psychol. 2002;7(pt 1)11-21.
8. Ahern DK, Gorkin L, Anderson JL, et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol. 1990;66:59-62.
9. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999-1005.
10. Vigo DE, Nicola Siri L, Landon De Guevara MS, et al. Relation of depression to heart rate nonlinear dynamics in patients > or =60 years of age with recent unstable angina pectoris or acute myocardial infarction. Am J Cardiol. 2004;93:756-760.
11. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701-709.
12. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108:939-944.
13. Musselman DL, Tomer A, Manatunga AC, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry. 1996;153:1313-1317.
14. Mc Adam C, Colaham FJ, Brophy J, et al. Alterations by a plasma factor of platelet aggregation and 5HT uptake in depression. Biol Psychol. 1992;32:296-298.
15. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm Res. 2001;43:453-462.
16. Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol. 2001;87:1398-1400.
17. Musselman DL, Marzec UM, Manatunga M, et al. Platelet reactivity in depressed patients treated with paroxetine. Arch Gen Psychiatry. 2000;57:875-882.
18. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994;31:229-239.
19. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195-202.
20. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation. 1999;99:620-625.
21. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann NY Acad Sci. 1993;677:293-308.
22. Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? Thromb Haemost. 1999;81:314-316.
23. Briley MS, Raisman R, Sechter D, et al. [3H]-Imipramine binding in human platelets: a new biochemical parameters in depression. Neuropharmacology. 1980;19:1209-1210.
24. Hrdina PD, Bakish D, Ravindran A, et al. Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment. J Psychiatry Res. 1997;66:73-85.
25. Dwivedi Y, Janicak PG, Pandey GN. Elevated [3H]inositol 1,4,5-trisphosphate binding sites and expressed inositol 1,4,5-trisphosphate receptor protein level in platelets of depressed patients. Psychopharmacology. 1998;138:47-54.
26. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. Platelet monoamine oxidase activity in elderly depressed out patients. Biol Psychiatry. 1986;21:1360-1364.
27. Wahlund B, Saaf J, Wetterberg L. Classification of patients with affective disorders using platelet monoamine oxidase activity, serum melatonin and post-dexamethasone cortisol. Acta Psychiatr Scand. 1995;91:313-321.
28. Reichborn-Kjennerud T, Lingjaerde O, Oreland L. Platelet monoamine oxidase activity in patients with winter seasonal affective disorder. Psychiatry Res. 1996;63:273-280.
29. Laghrissi-Thode F, Wagner WR, Pollock BG, et al. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry. 1997;42:290-295.
30. Musselman DL, Marzec U, Davidoff M, et al. Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. Depress Anxiety. 2002;15:91-101.
31. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry. 1988;suppl 49:46-51.
32. Tuomisto J, Tukiainen E. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature. 1976;262:596.
33. Coopen A, Swade C, Wood K. Platelet 5HT accumulation in depressive illness. Clin Chim Acta. 1978;87:165-168.
34. Biegon A, Weizman A, Karp L, et al. Serotonin 5-HT2 receptor binding on blood platelets - a peripheral marker for depression. Life Sci. 1987;40:2485-2492.
35. Sheline YI, Bardgett ME, Jackson JL, et al. Platelet serotonin markers and depressive symptomatology. Biol Psychiatry. 1995;37:442-447.
36. Delisi SM, Konopka LM, O'Connor FL, et al. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: relationship to symptomatology and medication. Biol Psychiatry. 1998;43:327-334.
37. Konopka LM, Cooper R, Crayton JW. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biol Psychiatry. 1996;39:708-713.
38. Menninger JA, Tabakoff B. Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression. Biol Psychiatry. 1997;42:30-38.
39. Garcia-Sevilla JA, Escriba PV, Busquets X, et al. Platelet imidazoline receptors and regulatory G proteins in patients with major depression. Neuroreport. 1996;8:169-172.
40. Karege F, Bovier P, Stepanian R, et al. The effect of clinical outcome on platelet G proteins of major depressed patients. Eur Neuropsychopharmacol. 1998;8:89-94.
41. Nugent DF, Dinan TG, Leonard BE. Alteration by a plasma factor(s) of platelet aggregation in unmedicated unipolar depressed patients. J Affect Disord. 1994;31:61-66.
42. Nugent DF, Dinan TG, Leonard BE. Further characterization of the inhibition of platelet aggregation by a plasma factor(s) in unmedicated unipolar depressed patients. J Affect Disord. 1995;33:227-231.
43. Maes M, Van der Planken M, Van Gastel A, et al. Blood coagulation and platelet aggregation in major depression. J Affect Disord. 1996;40:35-40.
44. Karege F, Bovier P, Hilleret H, et al. Adrenaline-induced platelet aggregation in depressed patients and control subjects. Neuropsychobiology. 1993;27:21-25.
45. Butler J, Leonard BE. The platelet serotonergic system in depression and following sertraline treatment. Int Clin Psychopharmacol. 1988;3:343-347.
46. Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996;30:1232-1234.
47. Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother. 1992;26:1517-1519.
48. Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. Ann Pharmacother. 1996;30:786-788.
49. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37:12-16.
50. Willerson JT, Yao SK, Ferguson JJ, et al. Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators. Tex Heart Inst J. 1991;18:243-247.
51. Serebruany VL, Malinin AI, Lowry DR, et al. Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events. J Cardiovasc Pharmacol. 2004;43:677-684.
52. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29:1102-1109.